ISPOR Europe 2019
Copenhagen schedule
Monday 4 November 2019
Posters
| Display hours | Session | Code | Title | Authors |
|---|---|---|---|---|
10:30-14:00 |
PNS: No specific disease |
PNS217 |
How central limit theorem relates to the selection of distributions for probabilistic sensitivity analysis |
Hale O, Lee D |
10:30-14:00 |
PNS: No specific disease |
PNS260 |
Inclusion of new strategies in the UK’s Cancer Drug Fund: what was decided in France? |
Trancart M, Almond C, Sullivan W |
15:30-19:00 |
PCN: Cancer |
PCN226 |
The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK |
Ntais D, Batteson R, Hart R, Hemstock M, Lee D |
15:30-19:00 |
PCN: Cancer |
PCN345 |
A review of differences in decision-making across NICE health technology assessments of nivolumab |
Horscroft J, Casson J, Sullivan W, Ntais D, Kiff C, Tyas D |
15:30-19:00 |
PCN: Cancer |
PCN346 |
Mean versus median: what does NICE consider to be the most appropriate statistic for estimating short life expectancy to satisfy end-of-life criteria? |
Raad A, Lee D |
15:30-19:00 |
PCN: Cancer |
PCN380 |
A targeted review evaluating uncertainty in single technology appraisal submissions for treatments approved for use since the introduction of the ‘new’ Cancer Drugs Fund |
Critchlow S, Lilley C, Gladwell D, Akehurst RL, Palmer S, Trevor N, Adedokun L, Lee JM |
15:30-19:00 |
PCN: Cancer |
PCN472 |
Patient reported health state utilities in cutaneous t-cell lymphoma (CTCL) – an analysis of EQ-5D and Skindex-29 data collected from the Alcanza trial |
Podkonjak T, McCarthy G, Cranmer H, Birnie R |
15:30-19:00 |
PCN: Cancer |
PCN530 |
Impact of subsequent treatment choice and surrogacy assumptions in hormone receptor-positive, HER2-Negative breast cancer treatment pathway modelling |
Ralph L, Pennington B |
Workshop
| Time | Code | Title | Discussion leaders | Location |
|---|---|---|---|---|
17:00-18:00 |
W8 |
Improving efficiency in HTA: the role of open source models and more advanced software choice |
Raquel Aguiar-Ibáñez, Gianluca Baio, Dawn Lee, R. Brett McQueen |
C1 M1 |
Tuesday 5 November 2019
Posters
| Display hours | Session | Code | Title | Authors |
|---|---|---|---|---|
10:30-14:00 |
PDB: Diabetes/Endocrine/Metabolic Disorders |
PDB32 |
Would a cohort-level approach to cost-effectiveness modelling have led to a different decision in an important NICE appraisal for obesity patients? |
Metry A, Sullivan W, Kearns B, Bullement A |
15:45-19:00 |
PCV: Cardiovascular Disorders |
PCV56 |
Cost-effectiveness of the sustained-release paclitaxel-eluting Eluvia stent compared to the paclitaxel-coated Zilver PTX stent for endovascular treatment of peripheral artery disease – a German Statutory Sickness Fund perspective |
Giretti C, Gray WA, Elroy P, Akehurst RL, Amorosi SL, Griffiths R, Müller-Hülsbeck S |
15:45-19:00 |
PCV: Cardiovascular Disorders |
PCV114 |
Feasibility of using real world evidence to inform decisions on conducting a cost effectiveness analysis- an example of stroke risk reduction therapies in atrial fibrillation |
Saunders O, Akehurst R, Zhong Y, Amorosi SL, Gavaghan M, Hemstock M, Wong T, Panikker S |
15:45-19:00 |
PMU: Multiple Diseases |
PMU82 |
Varying willingness-to-pay based on disease burden: Impact on health technology assessment outcomes of specialist drugs in the Netherlands |
Schurer M, Vossen CY, van Keep M, Horscroft J, Moorhouse JA, Chapman AM, Akehurst RL |
15:45-19:00 |
PMU: Multiple Diseases |
PMU114 |
Specialised health technology assessment processes for very rare diseases: past, present and future |
Akehurst RL, Moorhouse JA, Jones E, Mason N, Schurer M, Chapman AM, Horscroft J |
Wednesday 6 November 2019
Poster
| Display hours | Session | Code | Title | Authors |
|---|---|---|---|---|
09:30-14:00 |
PIH: Individual’s Health |
PIH20 |
A targeted literature review of the economic burden associated with polycystic ovary syndrome |
Rajora P, Goli N, Savner R, Singh A, Bhutani MK |
Issue Panel
| Time | Code | Title | Moderator | Panelists | Location |
|---|---|---|---|---|---|
08:30-09:30 |
IP19 |
How effective are managed access agreements as a vehicle for earlier reimbursement in the presence of uncertainty? Lessons from the new Cancer Drugs Fund |
Ron Akehurst |
Jennifer M Lee, Stephen Palmer, Steve Williamson |
C1 M0 |
Podium Presentation
| Time | Code | Title | Authors | Location |
|---|---|---|---|---|
14:15-14:30 |
RW2 |
Methodological approaches for incorporating real-world overall survival data into long-term survival estimates: case study of a NICE technology appraisal in extensive-stage small-cell lung cancer |
Connor S, Orfanos P, Flahavan E, Patterson K, Lee D |
C1 M4 |
